Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

All A·Important B·Normal #clinical trial ✕
B
[2 consecutive boards: Xiaofang Pharmaceutical: Drugs under development to treat hair loss are still in the preclinical research stage] On September 2, Xiaofang Pharmaceutical (603207.SH) issued an announcement of abnormal stock trading fluctuations. The company’s operating fundamentals have not changed. Its main business is the production, research and development and sales of external drugs. The products on sale are mainly household external drugs, and do not involve innovative drugs. The company is concerned about recent media reports about the company’s drug “Compound Platycladus Platycladus Tincture”, which is under development to treat hair loss. This drug is a Category 1.1 traditional Chinese medicine jointly developed by the company and Shanghai Dermatology Hospital. It is currently in the preclinical research stage and needs to submit a clinical trial application to the State Food and Drug Administration. There is uncertainty in subsequent research and development.
#clinical trial#A-share announcement express#A-share risk warning announcement09-02 18:23
B
[CSPC Innovation: SYS6010 included in the list of breakthrough therapies] On September 1, CSPC Innovation (300765.SZ) announced that SYS6010, developed by the company's holding subsidiary Jushi Biologics, was included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration. The proposed indication is for patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed immune and platinum-containing chemotherapy. SYS6010 is an antibody-drug conjugate targeting EGFR, and key Phase III clinical trials for this indication are currently underway. Previously, SYS6010 has received two breakthrough therapy designations, respectively for EGFR mutation-positive advanced non-small cell lung cancer and advanced esophageal squamous cell carcinoma.
#clinical trial#cell#A-share announcement express09-01 16:56
B
[CAR-T therapy significantly reduces the symptoms of severe rheumatoid arthritis] September 1st, Chimeric Antigen Receptor T-cell immunotherapy (CAR-T) is mainly used to treat cancer, but this type of personalized therapy prepared from the patient's own immune cells is also expected to be used for autoimmune diseases. German scientists reported the results of the world's first relevant clinical trial: After receiving CAR-T treatment, the symptoms of six patients with severe rheumatoid arthritis were significantly reduced, and three of them no longer needed any anti-rheumatic drugs at the end of the observation period. The relevant paper was published in the latest issue of Nature Medicine.
#clinical trial#medicine#cell#Global market intelligence09-01 07:11
A
[CSPC Pharmaceuticals Innovation: Its controlled subsidiary SYH2092 injection starts Phase I clinical trial] On August 31, CSPC Pharmaceutical Innovation (300765.SZ) announced that the company’s controlled subsidiary Jushi Biologics has recently launched the Phase I clinical trial of SYH2092 injection. SYH2092 is an amylin receptor agonist. By optimizing the agonistic activity and fatty acid modification, it is expected to have controllable tolerability while improving efficacy and bringing about lasting weight loss benefits. The product received a clinical trial approval notice from the State Food and Drug Administration in August 2026. This phase I clinical trial aims to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose in healthy participants, and is expected to bring clinical benefits to weight management in obese patients and blood sugar control in adult patients with type 2 diabetes. The trial has been launched in China, and participant recruitment and screening are being actively promoted.
#clinical trial#A-share announcement express08-31 19:08